Details
Stereochemistry | RACEMIC |
Molecular Formula | C33H44FN5O3 |
Molecular Weight | 577.7326 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)NC(=O)[C@@H]1CC[C@@H](CC1)N2C(NC(=O)C3=CC=C(F)C=C3)=NC4=C2C=C(CN5CCC(CC5)C(C)(C)O)C=C4
InChI
InChIKey=WSTUJEXAPHIEIM-FEGDYQJNSA-N
InChI=1S/C33H44FN5O3/c1-21(2)35-30(40)24-8-12-27(13-9-24)39-29-19-22(20-38-17-15-25(16-18-38)33(3,4)42)5-14-28(29)36-32(39)37-31(41)23-6-10-26(34)11-7-23/h5-7,10-11,14,19,21,24-25,27,42H,8-9,12-13,15-18,20H2,1-4H3,(H,35,40)(H,36,37,41)/t24-,27+
Molecular Formula | C33H44FN5O3 |
Molecular Weight | 577.7326 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Belizatinib, also known as TSR-011, is an orally available inhibitor of both the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) and the tropomyosin-related kinases (TRK) TRKA, TRKB, and TRKC, with potential antineoplastic activity. Upon administration, ALK/TRK inhibitor TSR-011 binds to and inhibits both ALK and TRK kinases. The inhibition leads to disruption of ALK- and TRK-mediated signaling and impedes tumor cell growth in ALK/TRK-overexpressing tumor cells. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development; ALK dysregulation and gene rearrangements are associated with a series of tumors.
Originator
Approval Year
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
3327.36 nM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/31217479 |
480 mg 1 times / day steady-state, oral dose: 480 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
BELIZATINIB plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
Sample Use Guides
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 10:18:31 GMT 2023
by
admin
on
Sat Dec 16 10:18:31 GMT 2023
|
Record UNII |
Z8A6022P3J
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
57345941
Created by
admin on Sat Dec 16 10:18:31 GMT 2023 , Edited by admin on Sat Dec 16 10:18:31 GMT 2023
|
PRIMARY | |||
|
C169804
Created by
admin on Sat Dec 16 10:18:31 GMT 2023 , Edited by admin on Sat Dec 16 10:18:31 GMT 2023
|
PRIMARY | |||
|
1388225-72-6
Created by
admin on Sat Dec 16 10:18:31 GMT 2023 , Edited by admin on Sat Dec 16 10:18:31 GMT 2023
|
ALTERNATIVE | |||
|
Z8A6022P3J
Created by
admin on Sat Dec 16 10:18:31 GMT 2023 , Edited by admin on Sat Dec 16 10:18:31 GMT 2023
|
PRIMARY | |||
|
10155
Created by
admin on Sat Dec 16 10:18:31 GMT 2023 , Edited by admin on Sat Dec 16 10:18:31 GMT 2023
|
PRIMARY | |||
|
100000174180
Created by
admin on Sat Dec 16 10:18:31 GMT 2023 , Edited by admin on Sat Dec 16 10:18:31 GMT 2023
|
PRIMARY | |||
|
1357920-84-3
Created by
admin on Sat Dec 16 10:18:31 GMT 2023 , Edited by admin on Sat Dec 16 10:18:31 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> INHIBITOR |
INHIBITOR
IC50
|
||
|
TARGET -> INHIBITOR |
INHIBITOR
IC50
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |